Table 2.
Best overall response assessed by IRC
| KN046 3 mg/kg Q2W + nab-paclitaxel (n = 15) | KN046 5 mg/kg Q2W + nab-paclitaxel (n = 10) | Totala (n = 25) | |
|---|---|---|---|
| Best overall response, n (%) | |||
| Complete response, CR | 1 (6.7%) | 0 | 1 (4.0%) |
| Partial response, PR | 8 (53.3%) | 2 (20.0%) | 10 (40.0%) |
| Stable disease, SD | 6 (40.0%) | 7 (70.0%) | 13 (52.0%) |
| Progressive disease, PD | 0 | 1 (10.0%) | 1 (4.0%) |
|
Objective response rate, ORR (95% CI) [CR + PR] |
60.0% (32.3–83.7%) |
20.0% (2.5–55.6%) |
44.0% (24.4–65.1%) |
|
Disease control rate, DCR (95% CI) [CR + PR + SD] |
100.0% (78.2–100.0%) |
90.0% (55.5–99.8%) |
96.0% (79.7–99.9%) |
|
Clinical benefit rate, CBR (95% CI) [CR + PR + SD ≥ 24 weeks] |
60.0% (32.3–83.7%) |
40.0% (12.2–73.8%) |
52.0% (31.3–72.2%) |
| Median DoR | Not reached | Not reached | Not reached |
aTwo patients withdrew from the trial before the first tumor assessment and were excluded from the evaluable population.
IRC independent review committee.